Cancer immunotherapy and nanomedicine (Q37785836)

23 August 2017

Cancer immunotherapy and nanomedicine (English)

1 reference

23 August 2017

1 reference

1 reference

Wei-Yun Sheng

1

1 reference

PubMed ID

20821040

23 August 2017

Leaf Huang

series ordinal

2

1 reference

23 August 2017

4 September 2010

1 reference

23 August 2017

Pharmaceutical Research

1 reference

23 August 2017

28

1 reference

23 August 2017

200-214

1 reference

23 August 2017

2

1 reference

IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity

23 August 2017

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0258-8

The three Es of cancer immunoediting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0258-8

The immunobiology of cancer immunosurveillance and immunoediting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0258-8

Therapeutic targeting of myeloid-derived suppressor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0258-8

Myeloid-derived suppressor cells as regulators of the immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0258-8

Mechanisms of tumor escape: role of tumor microenvironment in inducing apoptosis of cytolytic effector cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0258-8

PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0258-8

Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0258-8

Antitumor activity of cytokine-induced killer cells in nude mouse xenograft model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0258-8

The application of high-dose interleukin-2 for metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0258-8

Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0258-8

IL-21 enhances tumor-specific CTL induction by anti-DR5 antibody therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0258-8

Clinical and biological effects of recombinant human interleukin-18 administered by intravenous infusion to patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0258-8

A dose-escalation study of recombinant human interleukin-18 using two different schedules of administration in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0258-8

Increased immunogenicity of surviving tumor cells enables cooperation between liposomal doxorubicin and IL-18.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0258-8

Enhanced NK cell activity in mice injected with interferon and interferon inducers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0258-8

Interferon inhibits the generation of allospecific suppressor T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0258-8

Australia Antigen as a Marker of Propagation of the Serum Hepatitis Virus in Liver Cultures

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0258-8

Effects of recombinant leukocyte interferon (rIFN-alpha A) on tumour growth and immune responses in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0258-8

UK Medical Research Council randomised, multicentre trial of interferon-alpha n1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. The UK Medical Research Council's Working Parties for Therapeutic Trials in Adult

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0258-8

Phase 2 trial of interferon-beta as second-line treatment of ovarian cancer, fallopian tube cancer, or primary carcinoma of the peritoneum

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0258-8

A phase I clinical trial of single-dose intrapleural IFN-beta gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumor immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0258-8

Adoptive tumor therapy with T lymphocytes enriched through an IFN-gamma capture assay.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0258-8

A phase II study of GM-CSF and rIFN-gamma1b plus carboplatin for the treatment of recurrent, platinum-sensitive ovarian, fallopian tube and primary peritoneal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0258-8

Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0258-8

Interferon-gamma in combination with carboplatin and paclitaxel as a safe and effective first-line treatment option for advanced ovarian cancer: results of a phase I/II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0258-8

Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: results from a prospectively designed analysis o

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0258-8

Interferon-gamma expression is an independent prognostic factor in ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0258-8

Toll-like receptors and immune regulation: their direct and indirect modulation on regulatory CD4+ CD25+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0258-8

Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0258-8

Human effector CD8+ T lymphocytes express TLR3 as a functional coreceptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0258-8

Toll-like receptor agonists in the treatment of chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0258-8

Oligodeoxynucleotide CpG 7909 delivered as intravenous infusion demonstrates immunologic modulation in patients with previously treated non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0258-8

The use of Toll-like receptor-7 agonist in the treatment of basal cell carcinoma: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0258-8

Toll-like receptor 4 mediates an antitumor host response induced by Salmonella choleraesuis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0258-8

TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0258-8

KSP inhibitor ARRY-520 as a substitute for Paclitaxel in Type I ovarian cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0258-8

Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0258-8

Immunotherapeutic uses of CpG oligodeoxynucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0258-8

Antitumor activity of G3139 lipid nanoparticles (LNPs).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0258-8

Antibody-dependent antitumor cytotoxicity by human monocytes cultured with recombinant macrophage colony-stimulating factor. Induction of efficient antibody-mediated antitumor cytotoxicity not detected by isotope release assays

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0258-8

Phagocytosis of tumor cells by human monocytes cultured in recombinant macrophage colony-stimulating factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0258-8

Recombinant bispecific antibodies for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0258-8

Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0258-8

Phase 1 study of HPV16-specific immunotherapy with E6E7 fusion protein and ISCOMATRIX adjuvant in women with cervical intraepithelial neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0258-8

Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0258-8

Human tumor antigens for cancer vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0258-8

Ins and outs of clinical trials with peptide-based vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0258-8

In vivo targeting of dendritic cells in lymph nodes with poly(propylene sulfide) nanoparticles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0258-8

Design opportunities for actively targeted nanoparticle vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0258-8

Characterization of poly(D,L-lactic-co-glycolic acid) based nanoparticulate system for enhanced delivery of antigens to dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0258-8

Co-delivery of cancer-associated antigen and Toll-like receptor 4 ligand in PLGA nanoparticles induces potent CD8+ T cell-mediated anti-tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0258-8

Antitumor effect of all-trans retinoic acid-encapsulated nanoparticles of methoxy poly(ethylene glycol)-conjugated chitosan against CT-26 colon carcinoma in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0258-8

Nanoparticles built by self-assembly of amphiphilic gamma-PGA can deliver antigens to antigen-presenting cells with high efficiency: a new tumor-vaccine carrier for eliciting effector T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0258-8

EphA2-derived peptide vaccine with amphiphilic poly(gamma-glutamic acid) nanoparticles elicits an anti-tumor effect against mouse liver tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0258-8

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0258-8

Opportunities to improve the prevention and treatment of cervical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0258-8

A self-adjuvanting lipopeptide-based vaccine candidate for the treatment of hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0258-8

Highly immunogenic and totally synthetic lipopeptides as self-adjuvanting immunocontraceptive vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0258-8

Lipopeptide presentation pathway in dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0258-8

Recognition of lipopeptide patterns by Toll-like receptor 2-Toll-like receptor 6 heterodimer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0258-8

Lipopeptide-based melanoma cancer vaccine induced a strong MART-27-35-cytotoxic T lymphocyte response in a preclinal study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0258-8

Cytotoxic T lymphocyte response induced by an improved synthetic lipopeptide vaccine against cervical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0258-8

Direct gene transfer into mouse muscle in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0258-8

Genetic immunization is a simple method for eliciting an immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0258-8

Heterologous protection against influenza by injection of DNA encoding a viral protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0258-8

Induction of antigen-specific CD8+ T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0258-8

Generation of MHC class I-restricted cytotoxic T lymphocytes by expression of a viral protein in muscle cells: antigen presentation by non-muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0258-8

Granulocyte-macrophage colony-stimulating factor priming plus papillomavirus E6 DNA vaccination: effects on papilloma formation and regression in the cottontail rabbit papillomavirus--rabbit model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0258-8

Oral gene delivery with chitosan--DNA nanoparticles generates immunologic protection in a murine model of peanut allergy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0258-8

Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0258-8

Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0258-8

Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0258-8

In vivo targeting of dendritic cells for activation of cellular immunity using vaccine carriers based on pH-responsive microparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0258-8

Nanocarriers for systemic and mucosal vaccine delivery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0258-8

Pharmacokinetics and biodistribution of nanoparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0258-8

Delivery of lipids and liposomal proteins to the cytoplasm and Golgi of antigen-presenting cells. mangala.rao@na.amedd.army.mil

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0258-8

Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0258-8

Antigen presentation to cytotoxic T lymphocytes in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0258-8

Coating of mannan on LPD particles containing HPV E7 peptide significantly enhances immunity against HPV-positive tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0258-8

Cationic lipids direct a viral glycoprotein into the class I major histocompatibility complex antigen-presentation pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0258-8

Electroporation and commercial liposomes efficiently deliver soluble protein into the MHC class I presentation pathway. Priming in vitro and in vivo for class I-restricted recognition of soluble antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0258-8

Potentiation of cationic liposome-mediated gene delivery by polycations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0258-8

In vivo gene transfer via intravenous administration of cationic lipid-protamine-DNA (LPD) complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0258-8

Aspartoacylase gene transfer to the mammalian central nervous system with therapeutic implications for Canavan disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0258-8

Sequential injection of cationic liposome and plasmid DNA effectively transfects the lung with minimal inflammatory toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0258-8

Mechanism of adjuvant activity of cationic liposome: phosphorylation of a MAP kinase, ERK and induction of chemokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0258-8

Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0258-8

Manipulating the immune system: humoral versus cell-mediated immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0258-8

Mechanism of action of licensed vaccine adjuvants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0258-8

The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0258-8

Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0258-8

Antibodies to lipids and liposomes: immunology and safety.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0258-8

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0258-8

Selective induction of high avidity CTL by altering the balance of signals from APC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0258-8

Coadministration of HIV vaccine vectors with vaccinia viruses expressing IL-15 but not IL-2 induces long-lasting cellular immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0258-8

Calreticulin exposure dictates the immunogenicity of cancer cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0258-8

Molecular interactions between dying tumor cells and the innate immune system determine the efficacy of conventional anticancer therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0258-8

Chemotherapeutic agents in noncytotoxic concentrations increase antigen presentation by dendritic cells via an IL-12-dependent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0258-8

Cyclophosphamide resets dendritic cell homeostasis and enhances antitumor immunity through effects that extend beyond regulatory T cell elimination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0258-8

Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0258-8

Nanotechnology approaches to crossing the blood-brain barrier and drug delivery to the CNS

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0258-8

Cancer immunotherapy based on intracellular hyperthermia using magnetite nanoparticles: a novel concept of "heat-controlled necrosis" with heat shock protein expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0258-8

Post-mortem studies in glioblastoma patients treated with thermotherapy using magnetic nanoparticles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0258-8

The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0258-8

Targeted delivery of chemotherapeutics: tumor-activated prodrug therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0258-8

Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0258-8

Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0258-8

Exogenous Interferon and Inducers of Interferon in the Treatment of Balb/c Mice inoculated with RC19 Tumour Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0258-8

Interferon enhances the expression of Fc gamma receptors

21 January 2018

1 reference

12 December 2020

Systemic interleukin 2 therapy for human prostate tumors in a nude mouse model.

1 reference

12 December 2020

Biodegradable and biocompatible poly(DL-lactide-co-glycolide) microspheres as an adjuvant for staphylococcal enterotoxin B toxoid which enhances the level of toxin-neutralizing antibodies.

1 reference

12 December 2020

Phase I/II trial of interferon-beta-serine in patients with renal cell carcinoma: immunological and biological effects

1 reference

12 December 2020

Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response

1 reference

12 December 2020

Interferon-α, interferon-γ and sizofiran in the adjuvant therapy in ovarian cancer — a preliminary trial

1 reference

12 December 2020

Drug targeting in cancer therapy: the magic bullet, what next?

1 reference

12 December 2020

MHC class I-restricted presentation of exogenous antigen by thymic antigen-presenting cells in vitro and in vivo

1 reference

12 December 2020

Phase I trial of toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non Hodgkin's lymphoma

1 reference

12 December 2020

Immunogenicity and protection in small-animal models with controlled-release tetanus toxoid microparticles as a single-dose vaccine

1 reference

12 December 2020

Inhibition by interferon preparations of a solid malignant tumour and pulmonary metastasis in mice.

1 reference

12 December 2020

Exploiting lymphatic transport and complement activation in nanoparticle vaccines

1 reference

12 December 2020

Molecular basis for lack of expression of HLA class I antigens in human small-cell lung carcinoma cell lines

1 reference

12 December 2020

Phase II study of low-dose recombinant leukocyte A interferon in disseminated malignant melanoma

1 reference

12 December 2020

IFN-gamma induces apoptosis in ovarian cancer cells in vivo and in vitro

1 reference

12 December 2020

Morphological observations on the cellular and subcellular destination of intravenously administered liposomes.

1 reference

12 December 2020

Lipid–protamine–DNA-mediated antigen delivery to antigen-presenting cells results in enhanced anti-tumor immune responses

1 reference

12 December 2020

Immunization with Epstein-Barr Virus (EBV) peptide-pulsed dendritic cells induces functional CD8+ T-cell immunity and may lead to tumor regression in patients with EBV-positive nasopharyngeal carcinoma.

1 reference

12 December 2020

Induction of specific antitumor immunity in the mouse with the electrofusion product of tumor cells and dendritic cells

1 reference

12 December 2020

Alpha interferon treatment of low-grade B-cell non-Hodgkin's lymphomas, cutaneous T-cell lymphomas, and chronic lymphocytic leukemia

1 reference

12 December 2020

Interleukin 18 induces the sequential activation of natural killer cells and cytotoxic T lymphocytes to protect syngeneic mice from transplantation with Meth A sarcoma

1 reference

12 December 2020

Cancer immunotherapy using dendritic/tumour-fusion vaccine induces elevation of serum anti-nuclear antibody with better clinical responses

1 reference

12 December 2020

Evaluation of biodegradable microspheres as vaccine adjuvant for hepatitis B surface antigen

1 reference

12 December 2020

"Pathogen-mimicking" nanoparticles for vaccine delivery to dendritic cells

1 reference

12 December 2020

Delivery strategies of melanoma vaccines: an overview

1 reference

12 December 2020

Nano- and microparticles as adjuvants in vaccine design: success and failure is related to host natural antibodies

1 reference

12 December 2020

Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: a Phase I study of ZYC101.

1 reference

12 December 2020

Immunostimulation of dendritic cells by cationic liposomes

1 reference

12 December 2020

Direct in vitro evidence and in vivo analysis of the antiangiogenesis effects of interleukin 12.

1 reference

12 December 2020

Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma

1 reference

12 December 2020

LPD nanoparticles--novel nonviral vector for efficient gene delivery

1 reference

12 December 2020

Liposome vectors for in vivo gene delivery

1 reference

12 December 2020

Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma

1 reference

12 December 2020

Brain tumor therapy by combined vaccination and antisense oligonucleotide delivery with nanoparticles

1 reference

12 December 2020

Recent developments in leishmaniasis vaccine delivery systems

1 reference

12 December 2020

Delivery of MUC1 mucin peptide by Poly(d,l-lactic-co-glycolic acid) microspheres induces type 1 T helper immune responses

1 reference

12 December 2020

A simple but effective cancer vaccine consisting of an antigen and a cationic lipid

1 reference

12 December 2020

Antitumor effects of interferon preparations in mice

1 reference

12 December 2020

Managing toxicities of high-dose interleukin-2.

1 reference

12 December 2020

Separation of tumor-infiltrating lymphocytes from tumor cells in human solid tumors. A comparison between velocity sedimentation and discontinuous density gradients

1 reference

12 December 2020

Anomalies in transgenic mice carrying the human interleukin-2 gene.

1 reference

12 December 2020

Liposome-polycation-DNA (LPD) particle as a carrier and adjuvant for protein-based vaccines: therapeutic effect against cervical cancer

1 reference

12 December 2020

Interleukin-2 administration alters the CD4+FOXP3+ T-cell pool and tumor trafficking in patients with ovarian carcinoma

1 reference

12 December 2020

Role of interferon-gamma in mediating the antitumor efficacy of interleukin-12

1 reference

12 December 2020

The inhibitory role of CpG immunostimulatory motifs in cationic lipid vector-mediated transgene expression in vivo

1 reference

12 December 2020

Down-regulation of the transporter for antigen presentation, proteasome subunits, and class I major histocompatibility complex in tumor cell lines

1 reference

12 December 2020

Acquired immunity in nude mice induced by expression of the IL-2 or IL-4 gene in human pancreatic carcinoma cells and anti-tumor effect generated by in vivo gene transfer using retrovirus

1 reference

12 December 2020

Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice.

1 reference

12 December 2020

In vivo induction of dendritic cell-mediated cytotoxicity against allogeneic pancreatic carcinoma cells.

1 reference

12 December 2020

Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells

1 reference

12 December 2020

DNA vaccines: a review

1 reference

12 December 2020

Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells

1 reference

12 December 2020

10.1007/S11095-010-0258-8

Identifiers

DOI

1 reference

23 August 2017

1 reference

PubMed ID

20821040